Inflammatory pathways in atherosclerosis and acute coronary syndromes

American Journal of Cardiology

Volumn 88, Issue 8 SUPPL. 1, 2001, Pages 10-15

  Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RAMIPRIL; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PATHWAY; CLINICAL PRACTICE; DISEASE MARKER; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; PREDICTION; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0035909217     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01924-5     Document Type: Article

References (96)

1. Atherosclerosis: An inflammatory disease
2. Novel inflammatory markers of coronary risk: Theory versus practice
3. Inflammation, atherosclerosis, and cardiovascular risk: An epidemiologic view
4. Statins for stroke: The second story?
5. Historical review of research on atherosclerosis
6. Anitschkow and the cholesterol over-fed rabbit
7. Molecular determinants of atherosclerotic plaque vulnerability
8. T lymphocytes in aortic and coronary intimas: Their potential role in atherogenesis
9. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque
10. Changes in the endothelium of the aorta and the behavior of macrophages in experimental atheroma of rabbits
11. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions
12. Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats
13. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation
14. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium
15. Identification of an inducible endothelial-leukocyte adhesion molecule
16. The sensation and regulation of interactions with the extracellular environment: The cell biology of lymphocyte adhesion receptors
17. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis
18. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
19. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions
20. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis
21. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques
22. Cytokines as mediators of vascular pathology
23. Immunologic interactions of T lymphocytes with vascular endothelium
24. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis
25. Immune mechanisms in atherosclerosis
26. Molecular basis of the acute coronary syndromes
27. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice
28. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice
29. Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease: Relevance in superoxide anion generation
30. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris
31. NF-κB: Pivotal mediator or innocent bystander in atherogenesis?
32. Matrix metalloproteinases and cardiovascular disease
33. Matrix metalloproteinase system deficiencies and matrix degradation
34. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
35. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
36. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
37. Changing concepts of atherogenesis
38. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction
39. Atherosclerotic plaque rupture: Emerging insights and opportunities
40. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein
41. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
42. Apolipoprotein E and the apolipoprotein E-deficient mouse
43. Mouse models of atherosclerosis
44. Inflammatory markers of coronary risk
45. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction
46. Elevation of C-reactive protein in "active" coronary artery disease
47. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
48. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
49. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
50. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
51. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment
52. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
53. Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
54. Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and hemostasis
55. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
56. Inflammation, the endothelium, and the acute coronary syndromes
57. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
58. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
59. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study
60. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis
61. Associations between change in C-reactive protein and serum lipids during statin treatment
62. Long-term effects of pravastatin on plasma concentration of C-reactive protein
63. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
64. Renin angiotensin system and ASCVD
65. The renin-angiotensin-aldosterone system: A specific target for hypertension management
66. The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial ischemia
67. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease
68. Strategies to achieve coronary arterial plaque stabilization
69. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
70. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
71. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)
72. The Quinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function
73. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: A future therapeutic perspective
74. The nuclear receptor superfamily: The second decade
75. Thiazolidinediones
76. PPARgamma, the ultimate thrifty gene
77. Peroxisome proliferator-activated receptor-gamma: A versatile metabolic regulator
78. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
79. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
80. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
81. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
82. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
83. Atherosclerosis: The road ahead
84. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
85. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
86. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
87. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
88. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
89. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
90. PPARalpha activators inhibit tissue factor expression and activity in human monocytes
91. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
92. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
93. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group
94. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening
95. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
96. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)